Welcome to our dedicated page for Galera Therapeutics news (Ticker: GRTX), a resource for investors and traders seeking the latest updates and insights on Galera Therapeutics stock.
Galera Therapeutics, Inc. (GRTX) generates news that reflects the evolution of a clinical-stage biopharmaceutical company navigating complex oncology development and corporate transitions. Company press releases cover clinical trial updates, FDA regulatory interactions, strategic reviews, financing events, corporate restructuring, acquisitions, and asset sales.
Historically, Galera’s news has focused on its superoxide dismutase mimetic programs, including avasopasem manganese for radiotherapy-induced and cisplatin-related toxicities and rucosopasem manganese for use with stereotactic body radiation therapy in non-small cell lung cancer and locally advanced pancreatic cancer. Updates have included the FDA’s acceptance and priority review of the avasopasem New Drug Application, issuance of a Complete Response Letter, scheduling and outcomes of a Type A meeting, and decisions to halt the GRECO-1 and GRECO-2 trials following a futility analysis.
Financial result announcements provide context on research and development spending, general and administrative expenses, net losses, and cash runway expectations, alongside descriptions of workforce reductions and cost-saving measures. These releases also describe the engagement of financial advisors and the Board’s evaluation of strategic alternatives aimed at maximizing stockholder value, including potential mergers, asset sales, licensing arrangements, or dissolution.
More recent news highlights major corporate events such as the Board’s approval of a Plan of Liquidation and Dissolution, the adoption of a limited duration stockholder rights agreement, the acquisition of Nova Pharmaceuticals, Inc., and the subsequent asset purchase agreement with Biossil Inc. for Galera’s dismutase mimetics portfolio. In parallel, Galera’s communications describe a shift toward a pan-nitric oxide synthase inhibitor program in advanced breast cancer.
Investors and observers can use the GRTX news feed to follow developments in Galera’s clinical programs, regulatory milestones, strategic transactions, and capital structure decisions over time.
Galera Therapeutics (GRTX) announced a registered direct offering of 14,320,000 shares of common stock and accompanying warrants at an offering price of $2.095 per share. The gross proceeds are expected to be approximately $30 million before fees and expenses. The warrants are set to expire five years from issuance and have an exercise price of $1.97 per share. This offering is slated to close around February 17, 2023, pending customary conditions. Galera is actively pursuing the development of innovative cancer therapeutics, with avasopasem under priority review by the FDA for treating radiation-induced oral mucositis.
Galera Therapeutics, Inc. (GRTX) announced that the FDA has accepted its New Drug Application (NDA) for avasopasem manganese, targeting radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer (HNC). This priority review designation has set a PDUFA target date of August 9, 2023.
Avasopasem, if approved, would be the first drug to address SOM, impacting approximately 42,000 patients annually in the U.S. The NDA is backed by two significant clinical trials, showing meaningful reductions in SOM incidence and severity, suggesting potential cost savings by reducing hospitalizations and treatment interruptions.
Galera Therapeutics has submitted a New Drug Application (NDA) to the FDA for avasopasem, targeting severe oral mucositis (SOM) in head and neck cancer patients undergoing radiotherapy. Supported by two rigorous trials involving 678 patients, avasopasem has shown significant reductions in SOM incidence and severity. The drug, which also received Fast Track and Breakthrough Therapy designations, addresses an unmet need as no FDA-approved treatment currently exists for SOM, affecting about 42,000 U.S. patients annually.
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that President and CEO Mel Sorensen, M.D., will present at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 11:10 a.m. E.T. A live webcast will be available on Galera's Investors page and archived for 30 days post-event. Galera is focused on developing innovative treatments to enhance cancer radiotherapy, notably its product candidates avasopasem manganese and rucosopasem manganese, aimed at reducing toxicities and improving efficacy in cancer treatments.
Galera Therapeutics (GRTX) is poised to submit a New Drug Application (NDA) for avasopasem to the FDA by year-end 2022, aimed at treating radiotherapy-induced severe oral mucositis (SOM). Recent data presented at the ASTRO Annual Meeting revealed significant findings: tumor outcomes and overall survival rates were consistent with placebo, and a 50% reduction in chronic kidney disease incidence was noted in avasopasem patients. Financially, the company reported a reduced net loss of $16 million for Q3 2022, improving from $22.6 million in Q3 2021, supported by lower operational expenses.
Galera Therapeutics (GRTX) announced positive outcomes from its Phase 3 ROMAN trial for avasopasem, aimed at treating radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients. One-year data demonstrated comparable tumor outcomes and overall survival between avasopasem and placebo groups. Notably, chronic kidney disease incidence in avasopasem patients was reduced by 50%. The company plans to submit a New Drug Application (NDA) to the FDA by the end of 2022, continuing its focus on addressing significant unmet needs in cancer treatment.
Galera Therapeutics (GRTX) announced significant presentations at the upcoming ASTRO Annual Meeting, scheduled for October 23-26, 2022, in San Antonio, Texas. Key highlights include tumor outcomes from the Phase 3 ROMAN trial of avasopasem for severe oral mucositis, and final data from the Phase 2 AESOP trial for chemoradiotherapy-induced esophagitis. Additionally, the company will showcase the Phase 2 EUSOM trial of avasopasem and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that its CEO, Mel Sorensen, M.D., will speak at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 4:30 p.m. E.T. A live webcast of the presentation will be available on Galera's Investors page, with an archived version accessible for 30 days post-event. Galera focuses on developing innovative therapeutics to enhance radiotherapy for cancer patients, notably its candidates avasopasem manganese and rucosopasem manganese, targeting radiotherapy-induced toxicities and enhancing cancer treatment efficacy.
Galera Therapeutics (Nasdaq: GRTX) has appointed Dr. Eugene P. Kennedy as its new Chief Medical Officer, effective immediately. Dr. Kennedy, a seasoned oncologist with over 15 years of clinical development experience, will succeed Dr. Jon T. Holmlund, who is set to retire this year. The transition aims to support the NDA submission for avasopasem, an innovative treatment for radiotherapy-induced toxicities, expected by the end of 2022. Galera's leadership believes Dr. Kennedy's expertise will enhance their long-term clinical strategy and product development.
Galera Therapeutics (GRTX) announced its progress in clinical trials and financial results for Q2 2022. The company aims to submit a New Drug Application for avasopasem by year-end 2022. An oral presentation at the ASCO Annual Meeting highlighted positive outcomes from the Phase 3 ROMAN trial for treating radiotherapy-induced oral mucositis. Phase 1 data from the GRECO-1 trial demonstrated that rucosopasem combined with SBRT was well tolerated, with signs of anti-cancer activity. The company reported a net loss of $(14.6) million for the quarter.